MARKET

ALDX

ALDX

Aldeyra
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.820
-0.380
-7.31%
After Hours: 4.850 +0.03 +0.62% 19:19 07/10 EDT
OPEN
5.07
PREV CLOSE
5.20
HIGH
5.55
LOW
4.790
VOLUME
2.18M
TURNOVER
--
52 WEEK HIGH
8.05
52 WEEK LOW
1.480
MARKET CAP
143.59M
P/E (TTM)
-2.4127
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ALDX stock price target is 27.33 with a high estimate of 34.00 and a low estimate of 15.00.

EPS

ALDX News

More
65 Biggest Movers From Yesterday
Gainers MOGU Inc. (NASDAQ: MOGU) shares climbed 104.8% to close at $5.92 on Tuesday.
Benzinga · 3d ago
Aldeyra Therapeutics Inc (ALDX): Hedge Funds In Wait-and-See Mode
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of
Insider Monkey · 4d ago
Aldeyra sets sights on U.S. application for reproxalap in dry eye disease
Based on FDA feedback, Aldeyra Therapeutics (NASDAQ:ALDX) plans to launch two Phase 3 clinical trials evaluating lead drug reproxalap in patients with dry
seekingalpha · 4d ago
51 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 4d ago
Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease
Business Wire · 4d ago
Aldeyra Therapeutics shares are trading higher after the company announced a new drug application for dry eye disease.
Benzinga · 4d ago
Aldeyra Therapeutics Announces New Drug Application Development Plans For Dry Eye Disease
Top-Line Results from First of Two Planned Clinical Trials Based on Tear RASP Levels Expected by the End of 2020 New Drug Application Submission for Reproxalap in Dry Eye Disease Expected by the End of 2021 Based on
Benzinga · 4d ago
What Kind Of Investors Own Most Of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)?
Simply Wall St. · 07/03 16:15

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About ALDX

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.
More

Webull offers kinds of Aldeyra Therapeutics Inc stock information, including NASDAQ:ALDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALDX stock methods without spending real money on the virtual paper trading platform.